Advanced cell programming

An extensive cell programming capability

Engineered T cell immunotherapy products show significant efficacy for hematological malignancies

However, realization of the potential of this approach across a broad range of tumor types will require multiple technology solutions to address limitations of the current generation of therapies.

Our technological approach is the development of advanced T-cell engineering components designed to directly address clinical challenges. A focus on our early-stage pipeline incorporates multiple components in a single product.

Latest Abstracts & Publications

See all
New England Journal of Medicine
November 27 2024

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia

Obe-cel
Nature Medicine
November 11 2024

TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial

AUTO4
Blood Cancer Journal
March 11 2024

Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry

Control